Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.62 |
| ▸ | MET | P08581 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068180 | 0.85 | ABL1 (0.57) | ABL1NPC1RAB9AAURKBMEN1 | |
| SCHEMBL23901243 | 0.82 | ABL1 (0.64) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL6067958 | 0.82 | NPC1 (0.48) | ABL1NPC1RAB9AMEN1SCD | |
| SCHEMBL23900992 | 0.81 | ABL1 (0.73) | ABL1MET | |
| SCHEMBL6067899 | 0.81 | ABL1 (0.62) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL6068271 | 0.80 | ABL1 (0.65) | ABL1NPC1RAB9AMEN1SCD | |
| SCHEMBL3788533 | 0.79 | ABL1 (0.54) | ABL1MET | |
| SCHEMBL544509 | 0.79 | ABL1 (0.57) | ABL1METCYP3A4ALDH1A1POLB | |
| SCHEMBL6068317 | 0.79 | NPC1 (0.49) | ABL1NPC1RAB9AMEN1SCD | |
| SCHEMBL23901018 | 0.78 | ABL1 (0.86) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091227-B2 | Benzothiazole derivatives | ABBOTT GMBH & CO. KG (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | ABL1 7/4885MET 489/4885CYP3A4 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.